GenomeFrontier Therapeutics
GenomeFrontier is an innovation-driven therapeutic company focused on developing next-generation gene therapies. They leverage proprietary virus-free gene and cell engineering platforms, including the Quantum Engine™, to create therapies that aim to cure a wide range of diseases, including cancer. Their mission is to develop affordable and effective gene and cell therapies, with a vision of making advanced treatments accessible, efficacious, and safe. They are actively involved in clinical trials, research, and collaborations to advance gene therapy technologies, particularly in the field of CAR T cell therapy.
Industries
Nr. of Employees
small (1-50)
GenomeFrontier Therapeutics
Patents
Products
Dual-targeting CAR T therapy for B cell malignancies (autologous)
An autologous CAR T therapy with dual antigen targeting and integrated safety-switch designed for treatment of B cell hematological malignancies; currently at IND and early clinical evaluation.
Multiplex-targeting armored CAR T for solid tumors
A multi-target, armored CAR T product concept designed with multiplex gene payloads and cell quality enrichment for potential treatment of solid tumors.
Clinical-stage pipeline of engineered cell therapies
A portfolio of engineered cell therapy candidates leveraging virus-free delivery, multiplex gene designs, and cell expansion technologies for hematologic and solid tumor indications.
qCART
A virus-free Quantum Engine for developing CAR T cell therapy that synergistically integrates four platforms for rapid and cost-effective manufacturing of clinical-scaled CAR T cells.
Quantum Engine
A robust cell-engineering system leveraging four proprietary virus-free gene and cell engineering platforms to potentially cure a wide range of diseases including cancer.
iCellar
A proprietary cell expansion platform composed of agents and/or gene-modified cells designed to enhance cell expansion capacity while maintaining cell quality and stemness for clinical-scale cell therapy.
Dual-targeting CAR T therapy for B cell malignancies (autologous)
An autologous CAR T therapy with dual antigen targeting and integrated safety-switch designed for treatment of B cell hematological malignancies; currently at IND and early clinical evaluation.
Multiplex-targeting armored CAR T for solid tumors
A multi-target, armored CAR T product concept designed with multiplex gene payloads and cell quality enrichment for potential treatment of solid tumors.
Clinical-stage pipeline of engineered cell therapies
A portfolio of engineered cell therapy candidates leveraging virus-free delivery, multiplex gene designs, and cell expansion technologies for hematologic and solid tumor indications.
qCART
A virus-free Quantum Engine for developing CAR T cell therapy that synergistically integrates four platforms for rapid and cost-effective manufacturing of clinical-scaled CAR T cells.
Quantum Engine
A robust cell-engineering system leveraging four proprietary virus-free gene and cell engineering platforms to potentially cure a wide range of diseases including cancer.
iCellar
A proprietary cell expansion platform composed of agents and/or gene-modified cells designed to enhance cell expansion capacity while maintaining cell quality and stemness for clinical-scale cell therapy.
Services
Collaborative access to a virus-free cell and gene engineering platform for academic and industry partners to advance development and commercialization of cell therapies.
Provision of information and contact for use of a cell expansion system designed to produce high-quality, stem-like T cell populations at clinical scale.
Design, construction, and iterative functional screening of therapeutic gene constructs using a library-based, virus-free approach and in vitro/in vivo evaluation systems.
Experience supporting IND submissions and initiation of early-phase clinical trials through regulatory engagement and first-in-human study execution.
Collaborative access to a virus-free cell and gene engineering platform for academic and industry partners to advance development and commercialization of cell therapies.
Provision of information and contact for use of a cell expansion system designed to produce high-quality, stem-like T cell populations at clinical scale.
Design, construction, and iterative functional screening of therapeutic gene constructs using a library-based, virus-free approach and in vitro/in vivo evaluation systems.
Experience supporting IND submissions and initiation of early-phase clinical trials through regulatory engagement and first-in-human study execution.
Expertise Areas
- Non-viral gene delivery and transposon systems
- Cell therapy manufacturing and scale-up
- Design and screening of therapeutic gene constructs
- Preclinical in vitro and in vivo model development
Key Technologies
- Transposon-based gene integration
- Electroporation / nucleofection
- Artificial antigen-presenting cells (aAPCs)
- Stem-like memory T cell (TSCM) enrichment
News & Updates
Demonstrates the potential of the qCART™ platform in gene therapy.
Paving the way for the future of gene and cell therapy.
To advance non-viral CAR T cell therapy GF-CART01.
Sareina Wu and Howard Cheng to present their work.
European Patent for Quantum pBac Transposon System
Granted in June, a major milestone for the company's gene editing technology.
IND Clearance for GF-CART01 in Taiwan
Received approval for clinical trial of dual targeting CAR T cell therapy.
Demonstrates the potential of the qCART™ platform in gene therapy.
Paving the way for the future of gene and cell therapy.
To advance non-viral CAR T cell therapy GF-CART01.
Sareina Wu and Howard Cheng to present their work.
European Patent for Quantum pBac Transposon System
Granted in June, a major milestone for the company's gene editing technology.
IND Clearance for GF-CART01 in Taiwan
Received approval for clinical trial of dual targeting CAR T cell therapy.